371 related articles for article (PubMed ID: 27323349)
1. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH; Litière S; Sleijfer S; Benson C; Italiano A; Kasper B; Messiou C; Gelderblom H; Wardelmann E; Le Cesne A; Blay JY; Marreaud S; Hindi N; Desar IME; Gronchi A; van der Graaf WTA
Int J Cancer; 2018 Jun; 142(12):2610-2620. PubMed ID: 29383713
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
4. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
6. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.
Verschoor AJ; Litière S; Marréaud S; Judson I; Toulmonde M; Wardelmann E; van der Graaf WT; Le Cesne A; Gronchi A; Gelderblom H
Eur J Cancer; 2018 May; 94():187-198. PubMed ID: 29574364
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
9. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
10. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity.
Eroglu A; Kocaoglu H; Demirci S; Akgül H
Eur J Surg Oncol; 2000 Apr; 26(3):213-21. PubMed ID: 10753532
[TBL] [Abstract][Full Text] [Related]
13. Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?
Posch F; Leitner L; Bergovec M; Bezan A; Stotz M; Gerger A; Pichler M; Stöger H; Liegl-Atzwanger B; Leithner A; Szkandera J
Clin Orthop Relat Res; 2017 May; 475(5):1427-1435. PubMed ID: 28083752
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients.
Iqbal N; Shukla NK; Deo SV; Agarwala S; Sharma DN; Sharma MC; Bakhshi S
Clin Transl Oncol; 2016 Mar; 18(3):310-6. PubMed ID: 26243399
[TBL] [Abstract][Full Text] [Related]
15. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score.
Schaefer IM; Hornick JL; Barysauskas CM; Raut CP; Patel SA; Royce TJ; Fletcher CDM; Baldini EH
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):375-383. PubMed ID: 28463157
[TBL] [Abstract][Full Text] [Related]
16. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Pasquali S; Colombo C; Pizzamiglio S; Verderio P; Callegaro D; Stacchiotti S; Martin Broto J; Lopez-Pousa A; Ferrari S; Poveda A; De Paoli A; Quagliuolo V; Jurado JC; Comandone A; Grignani G; De Sanctis R; Palassini E; Llomboart-Bosch A; Dei Tos AP; Casali PG; Picci P; Gronchi A
Eur J Cancer; 2018 Apr; 93():28-36. PubMed ID: 29475197
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Van Glabbeke M; van Oosterom AT; Oosterhuis JW; Mouridsen H; Crowther D; Somers R; Verweij J; Santoro A; Buesa J; Tursz T
J Clin Oncol; 1999 Jan; 17(1):150-7. PubMed ID: 10458228
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting prognosis and treatment strategies in metastatic soft tissue sarcomas: twenty years of experience.
İlhan A; Eraslan E; Yildiz F; Arslan ÜY; Alkiş N
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6465-6472. PubMed ID: 34787850
[TBL] [Abstract][Full Text] [Related]
20. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]